Main topics

  • Rare diseases
  • Experimental models
  • Delivery of therapies

Keynote speakers

Invited speakers

Dear Colleagues,

It is my great pleasure to invite you to the sixth CCP Phenogenomics Conference.

The scientific committee has selected the topic of rare diseases: experimental models & delivery of therapies as the main thematic focus of this year Conference.

We believe that the Conference will provide again an excellent opportunity to support networking and interactions among the researchers, CCP staff, users and experts from the commercial sector.

We are looking forward to meeting you either in Prague or virtually in September 2024.

Yours sincerely,

Radislav Sedlacek
Director of the Czech Centre for Phenogenomics
Institute of Molecular Genetics of the Czech Academy of Sciences

Czech Centre for Phenogenomics (CCP)

CCP is a large research infrastructure unique in combining genetic engineering capabilities, advanced phenotyping and imaging modalities, SPF animal housing and husbandry, as well as cryopreservation and archiving, all in one central location – at BIOCEV campus.

Through its membership in INFRAFRONTIER and IMPC, CCP is a partner in a global network that aims to comprehensively and systematically analyze the effect of loss of function gene mutations in mice. The goal is to produce a comprehensive ‘encyclopedia‘ of gene function, that will help identify causative factors of human diseases as well as novel targets for therapeutic intervention.

The conference is organized within the scope of the research programme “Towards Precision Medicine and Gene Therapy” of the Strategy AV21 supported by the Czech Academy of Sciences.

imagealttext

The conference covers topics related to the research focus of the National centre for new methods of diagnosis, monitoring, treatment and prevention of genetic diseases This project (ID: TN02000132, 2023 – 2026) is co-funded with state aid by the Technology Agency of the Czech Republic in the framework of the Programme National Centres of Competence.